HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2008. Nymox reported a net loss of $1,232,063, or $0.04 per share for the quarter ending March 31, 2008, compared to $1,132,520, or $0.04 per share for same period in 2007. The increase in the net loss is attributable to increased expenditures required for the maintenance of the Company’s patents. Product sales amounted to $104,484 for the first quarter of 2008, compared to $136,404 for the same period in 2007. The weighted, diluted average number of common shares at March 31, 2008 was 29,462,138, compared to 28,515,596 at March 31, 2007.
